{"id":"W2136977965","doi":"10.1200/jco.2007.15.9947","title":"Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":510,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Genentech; American Society of Clinical Oncology","keywords":"Medicine; Bevacizumab; Hepatocellular carcinoma; Internal medicine; Vascular endothelial growth factor; Gastroenterology; Angiogenesis; Oncology; Adverse effect; Phases of clinical research; Clinical trial; Chemotherapy; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001544968,0.001141232,0.002055055,0.0002689119,0.0002243821,0.0006558704,0.0005201074,0.0008203315,0.003401153],"category_scores_gemma":[0.001479126,0.0003565474,0.0006771584,0.0003185658,0.0005822035,0.0005150933,0.0002728585,0.002117174,0.0005464929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007547958,"about_ca_system_score_gemma":0.001131722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006785703,"about_ca_topic_score_gemma":0.001753018,"domain_scores_codex":[0.9995552,0.00027962,0.00002466272,0.00004616343,0.00003287308,0.00006148303],"domain_scores_gemma":[0.9989606,0.0002958233,0.000218823,0.00005244938,0.00005340934,0.000418897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8690491,0.02178371,0.006459641,0.001048295,0.001175526,0.000303196,0.000121896,0.001817313,0.02174346,0.0001525074,0.002672114,0.07367321],"study_design_scores_gemma":[0.7678149,0.2164014,0.00879948,0.00005120273,0.0004151131,0.0002561397,0.00003176462,0.001474833,0.002975393,0.0001064591,0.001658942,0.0000144883],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884626,0.005342981,0.0007240727,0.0007152836,0.0002422603,0.002286852,0.00063677,0.00008589065,0.001503225],"genre_scores_gemma":[0.9912897,0.001934274,0.001156971,0.0007403554,0.0002500579,0.001947473,0.001292779,0.00001749296,0.001370798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003401153,"threshold_uncertainty_score":0.01137799,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4016800966902733,"score_gpt":0.4960715878263401,"score_spread":0.09439149113606682,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}